Elgin Hoffmann

Elgin Hoffmann is a Physician Scientist specializing in Radiation Oncology at a clinical institute focused on uro-oncology, neuro-oncology, pediatric radio-oncology, and sarcomas. His work bridges clinical practice with translational research, particularly in CNS tumors and biomarker-guided therapies.

His research interests include:

• Development of biomarker-guided therapies for nervous system tumors
• Optimizing radiation therapy protocols for CNS lymphomas and meningiomas
• Investigating prognostic factors like SSTR2A expression in meningiomas
• Exploring neurobiological mechanisms in autistic trait-associated social cognition

Recent publications demonstrate a focus on precision oncology and radiation treatment optimization, with co-authorship on 2025 studies about adjuvant therapy in penile cancer and 2024 work on low-dose radiotherapy for skin lesions. While no formal awards are listed, his collaborative research spans multiple institutions including University Hospital Tuebingen and German Society of Radiation Oncology networks.

Key affiliations include the University Clinic for Radiation Oncology, with clinical expertise in neuro-oncology and pediatric radio-oncology. His technical focus areas encompass molecular subtyping, survival analysis, and advanced imaging applications in glioblastoma prognosis.